


(51) International Patent Classification:
Not classified(21) International Application Number:
PCT/US2021/038740(22) International Filing Date:
23 June 2021 (23.06.2021)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
63/043,114 23 June 2020 (23.06.2020) US
63/111,459 09 November 2020 (09.11.2020) US(71) Applicant: **KADMON CORPORATION, LLC** [US/US];
450 East 29th Street, New York, NY 10016 (US).(72) Inventors: **LU, Dan**; 24 Olde Woods Lane, Montvale, NJ 07645 (US). **POLONSKAYA, Zhanna**; 234 Central Avenue, Mountainside, NJ 07092 (US). **CHANG, Tzu-Pei**; 108 East 38th Street, New York, NY 10016 (US). **MARTOMO, Stella, A.**; 36 Columbia Terrace, Edgewater, NJ 07020 (US). **PATEL, Jeegar**; 3 Galligen Drive, Hillsborough, NJ 08844 (US). **MIYARA, Faical**; 57 Northway, Bronxville, NY 10708 (US).(74) Agent: **SOMERVILLE, Deborah, A.** et al.; Fox Rothschild LLP, 997 Lenox Drive, Lawrenceville, NJ 08648-2311 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-PD-1 ANTIBODIES AND FUSION PROTEINS



1C-antibody/IL-15

2C-antibody/IL-15



1N-antibody/IL-15

2N-antibody/IL-15

Fig. 21A

(57) Abstract: Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*